Latest Oncology News

Best Practices for Virtual Conference Presentations

Best Practices for Virtual Conference Presentations

October 16th 2021

Curtis Lachowiez, MD

As the autumn and winter conference season approaches, Curtis Lachowiez, MD, reflects on the impact 2020 left on the field of oncology.

Miami Cancer Institute’s HIV/Cancer Clinic Utilizes Multidisciplinary Care to Improve Outcomes

Miami Cancer Institute’s HIV/Cancer Clinic Utilizes Multidisciplinary Care to Improve Outcomes

October 15th 2021

Kristi Rosa

Marco Ruiz, MD, discusses the new HIV/Cancer Clinic and its goals, challenges faced with patients who have cancer and HIV infection, and clinical trial opportunities that strive to move the needle forward.

Pembrolizumab/Lenvatinib Approaches EU Approval for Select RCC and Endometrial Carcinoma

Pembrolizumab/Lenvatinib Approaches EU Approval for Select RCC and Endometrial Carcinoma

October 15th 2021

Kristi Rosa

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding approval of the combination of pembrolizumab and lenvatinib for 2 indications: select patients with renal cell carcinoma and select patients with endometrial carcinoma.

ADCs, Checkpoint Inhibitors Generate Discussion at ESMO 2021 in Lung Cancer

ADCs, Checkpoint Inhibitors Generate Discussion at ESMO 2021 in Lung Cancer

October 15th 2021

Caroline Seymour

Alexander I. Spira, MD, PhD, FACP, discusses impactful data from the 2021 ESMO Congress in lung cancer.

Tremelimumab Plus Durvalumab Improves Survival in Frontline Unresectable HCC

Tremelimumab Plus Durvalumab Improves Survival in Frontline Unresectable HCC

October 15th 2021

Kristi Rosa

A single, high priming dose of tremelimumab plus durvalumab resulted in a statistically significant and clinically meaningful improvement in overall survival vs sorafenib when used in the frontline treatment of patients with unresectable hepatocellular carcinoma who had not previously received systemic therapy and were not eligible for localized treatment.

Latest Oncology Videos

All Oncology News

Entospletinib Plus Obinutuzumab Shows Early Efficacy, Tolerability in High-Risk Relapsed/Refractory CLL

October 13th 2021

Maggie Tibbitt

Alexey Danilov, MD, PhD, discussed the data on entospletinib/obinutuzumab in patients with R/R CLL and suggests further research directions with this drug combination.

Dr. Johnson on the Promise of DS-7300 in SCLC and Other Advanced Solid Tumors

October 13th 2021

Melissa L. Johnson, MD

Melissa L. Johnson, MD, discusses the promise of DS-7300 in small cell lung cancer and other advanced solid tumors.

What Are the Current Treatment Options in Lung Cancer?

October 13th 2021

Sandip Patel, MD, an associate professor of medical oncology at University of California San Diego, explains the optimal diagnostic strategies that can be utilized to better inform biomarker-based therapies in lung cancer.

Dr. Spira on the Results of the TROPION-PanTumor01 Trial in NSCLC

October 13th 2021

Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

Alexander I. Spira, MD, PhD, FACP, discusses the results of the phase 1 TROPION-PanTumor01 trial in non–small cell lung cancer.

Dr. Verstovsek on the Benefit of JAK Inhibitor Combos in Myelofibrosis

October 13th 2021

Srdan Verstovsek, MD, PhD

Srdan Verstovsek, MD, PhD, discusses the benefit of drug combinations to improve anemia in patients with myelofibrosis.

Dr. Blue on Treatment Considerations for Relapsed/Refractory Multiple Myeloma

October 13th 2021

Brandon Blue, MD

Brandon Blue, MD, discusses treatment considerations for patients with relapsed/refractory multiple myeloma.

Effective Lung Cancer Screening Leads to Opportunities

October 13th 2021

James L. Mulshine, MD, professor of internal medicine, and associate director of Institute of Translation Medicine at Rush University, discusses the benefits of establishing a timely and investigation-informed screening and referral practice for patients who are at risk for developing lung cancer.

BTK Inhibitors, PI3K Inhibitors, and CAR T-Cell Therapy Shake Up Hematologic Malignancies Armamentarium

October 13th 2021

Jessica Hergert

Harry Paul Erba, MD, PhD, spotlights practice-changing data that emerged in recent years in hematologic malignancies and speaks to remaining questions, particularly with CAR T-cell therapy, in each paradigm.

Introduction to Lung Cancer Screening and Treatment

October 13th 2021

The second part of the webinar Lung Cancer Screening and Treatment: What's Next? focuses on the review of lung cancer screening and treatment status amid the COVID-19 pandemic. Participating faculty include Albert Rizzo, MD, FCCP, FACP, FAASM; James L. Mulshine, MD; Andrea Borondy Kitts, MS, MPH; and Sandip Patel, MD.

CAR T-cell Therapy CTX110 Shows Early Promise for Relapsed/Refractory CD19+ B-cell Malignancies

October 13th 2021

Kristi Rosa

The allogeneic CD19-targeted CAR T-cell therapy CTX110 was found to elicit encouraging responses with favorable tolerability in patients with relapsed or refractory B-cell malignancies, according to data from the phase 1 CARBON trial.

Cancer Treatment Centers of America Selects Lyniate as Strategic Interoperability Solution, Putting Patients at the Center of Innovation

October 13th 2021

Corepoint Integration Engine chosen to Streamline Connectivity Across Care Teams, Affiliate Networks, and Cancer Community, Extending Access to World-class Care for Patients Everywhere.

IO Combo Anchors a New Front Line Taking Shape in Unresectable HCC

October 13th 2021

Anita T. Shaffer

The tide is starting to turn toward more effective frontline systemic therapies for patients with unresectable hepatocellular carcinoma as a result of the introduction of a novel immune-oncology combination.

FDA Approves Pembrolizumab Plus Chemo With or Without Bevacizumab for Frontline Cervical Cancer

October 13th 2021

Kristi Rosa

The FDA has approved pembrolizumab for use in combination with chemotherapy, with or without bevacizumab, in patients with persistent, recurrent or metastatic cervical cancer whose tumors have a PD-L1 combined positive score of 1 or higher, as determined by an FDA-approved test.

Analysis Examines Real-World Survival Outcomes With Frontline Combos in Metastatic RCC

October 13th 2021

Kristi Rosa

The 18-month survival rates observed with axitinib plus pembrolizumab vs ipilimumab plus nivolumab in the frontline treatment of patients with metastatic renal cell carcinoma were not found to be statistically different.

FDA Approves Adjuvant Abemaciclib Plus Endocrine Therapy for Select HR+ Early Breast Cancer

October 13th 2021

Kristi Rosa

The FDA has approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of 20% or higher, as determined by an FDA-approved test.

See All News